The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.
Fiche publication
Date publication
janvier 2019
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEJEAN Sophie, Pr BINQUET Christine, Pr LEJEUNE Catherine, Pr QUANTIN Catherine
Tous les auteurs :
Binquet C, Lejeune C, Seror V, Peyron F, Bertaux AC, Scemama O, Quantin C, Béjean S, Stillwaggon E, Wallon M
Lien Pubmed
Résumé
Congenital Toxoplasmosis (CT) can have severe consequences. France, Austria, and Slovenia have prenatal screening programs whereas some other countries are considering universal screening to reduce congenital transmission and severity of infection in children. The efficiency of such programs is debated increasingly as seroprevalence among pregnant women and incidence of congenital toxoplasmosis show a steady decrease. In addition, uncertainty remains regarding the effectiveness of pre- and postnatal treatments.
Référence
PLoS ONE. 2019 ;14(9):e0221709